JosÃ© HernÃ¡ndez-RodrÃguez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3524089/publications.pdf

Version: 2024-02-01

135	5,997	57758	76900
papers	citations	44 h-index	74 g-index

143	143	143	4143
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy of canakinumab in a patient with adult-onset glucocorticoid-resistant periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. Modern Rheumatology Case Reports, 2023, 7, 276-279.	0.7	1
2	Efficacy and safety of TNF-Î± antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology, 2022, 61, 1376-1384.	1.9	26
3	Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. Rheumatology, 2022, 61, 1204-1210.	1.9	7
4	Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. European Journal of Internal Medicine, 2022, 95, 61-66.	2.2	12
5	Low serum osteocalcin levels are associated with diabetes mellitus in glucocorticoid treated patients. Osteoporosis International, 2022, 33, 745-750.	3.1	8
6	CHARACTERIZING COVID-19â€“RELATED RETINAL VASCULAR OCCLUSIONS. Retina, 2022, 42, 465-475.	1.7	14
7	Anakinra-induced psoriasis in a patient with Schnitzler's syndrome. Clinical and Experimental Rheumatology, 2022, 40, 191-192.	0.8	3
8	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. Frontiers in Medicine, 2022, 9, 878797.	2.6	9
9	MO241: Nets and Terminal Complement Pathway as Potential Biomarkers for Complement Overactivation Assessment in Anca-Associated Vasculitis. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
10	Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids. Annals of the Rheumatic Diseases, 2022, 81, 1290-1300.	0.9	20
11	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. Lupus, 2022, 31, 1344-1354.	1.6	4
12	Simultaneous presentation of granulomatosis with polyangiitis (GPA) and immunoglobulin G4-related disease (IgG4-RD). Leaving an open question: widening the spectrum of a single disease or real overlap?. Modern Rheumatology Case Reports, 2021, 5, 108-112.	0.7	4
13	Single-Organ Genitourinary Vasculitis. Rare Diseases of the Immune System, 2021, , 241-253.	0.1	1
14	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110371.	2.7	1
15	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. Rheumatology, 2021, 60, 5705-5712.	1.9	4
16	POS0121â€…RESPONSE OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TO MEPOLIZUMAB ACCORDING TO DISEASE MANIFESTATIONS. A SINGLE CENTRE EXPERIENCE. Annals of the Rheumatic Diseases, 2021, 80, 272.1-272.	0.9	1
17	Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis. Scientific Reports, 2021, 11, 14404.	3.3	8
18	Spectrum of Disease Manifestations in Patients with Selective Immunoglobulin E Deficiency. Journal of Clinical Medicine, 2021, 10, 4160.	2.4	8

#	Article	IF	Citations
19	Anakinra-induced psoriasis in a patient with Schnitzler's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
20	ANCA-associated vasculitic neuropathy during treatment with ipilimumab. Rheumatology, 2020, 59, 251-252.	1.9	7
21	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology, 2020, 59, 1574-1580.	1.9	47
22	Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. RMD Open, 2020, 6, e001355.	3.8	5
23	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Î± Receptorâ€"Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-12.	3.0	24
24	Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. Expert Opinion on Biological Therapy, 2020, 20, 717-723.	3.1	20
25	Successful treatment of severe COVID-19 with subcutaneousÂanakinra as a sole treatment. Rheumatology, 2020, 59, 2171-2173.	1.9	17
26	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-6.	3.0	7
27	Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide. Frontiers in Immunology, 2020, 11, 865.	4.8	48
28	Editorial: Autoinflammatory Diseases: From Genes to Bedside. Frontiers in Immunology, 2020, 11, 1177.	4.8	7
29	Rituximab treatment for IgA vasculitis: A systematic review. Autoimmunity Reviews, 2020, 19, 102490.	5.8	32
30	New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. Mediators of Inflammation, 2020, 2020, 1-6.	3.0	15
31	THU0305â€...PREVALENCE AND CLINICAL OUTCOME OF INTERSTITIAL LUNG DISEASE IN ANCA ASSOCIATED VASCULITIS. Annals of the Rheumatic Diseases, 2020, 79, 381.2-381.	0.9	0
32	SAT0467â€...LOW SERUM OSTEOCALCIN LEVELS ARE ASSOCIATED WITH THE PRESENCE OF DIABETES MELLITUS IN GLUCOCORTICOID TREATED PATIENTS.. Annals of the Rheumatic Diseases, 2020, 79, 1191.1-1191.	0.9	0
33	Effectiveness of TNF-Î± blockade in the treatment of refractory non-infectious scleritis: a multicentre study. Clinical and Experimental Rheumatology, 2020, 38, 1138-1144.	0.8	4
34	A very late presentation of polymyalgia rheumatica in a patient with giant cell arteritis: recurrence or casual association?. Modern Rheumatology Case Reports, 2019, 3, 130-133.	0.7	0
35	Dermatologic and Dermatopathologic Features of Monogenic Autoinflammatory Diseases. Frontiers in Immunology, 2019, 10, 2448.	4.8	29
36	THU0588â€...CLINICAL PHENOTYPES OF IGG4-RELATED DISEASE IN SPAIN. , 2019, , .		0

#	Article	IF	Citations
37	FRI0487â€...UTILITY OF TRABECULAR BONE SCORE(TBS) FOR FRACTURE RISK ASSESSMENT IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS. , 2019, , .		2
38	FRI0466â€...RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF FRACTURES IN GLUCOCORTICOID TREATED PATIENTS. THE ROLE OF HYPOGONADISM. , 2019, , .		0
39	Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases. Medicina ClÃ¡nica, 2019, 152, 502-507.	0.6	19
40	HIV-associated vasculitis. Part II: histologic and angiographic diagnostic reconfirmation after an uncontrolled HIV infection and fatal outcome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 151-152.	0.8	1
41	Nasoseptal Perforation: from Etiology to Treatment. Current Allergy and Asthma Reports, 2018, 18, 5.	5.3	44
42	Enfermedades autoinflamatorias monogÃ©nicas: conceptos generales y presentaciÃ³n en pacientes adultos. Medicina ClÃ¡nica, 2018, 150, 67-74.	0.6	8
43	Monogenic autoinflammatory diseases: General concepts and presentation in adult patients. Medicina ClÃ¡nica (English Edition), 2018, 150, 67-74.	0.2	2
44	Biological treatments in giant cell arteritis & Takayasu arteritis. European Journal of Internal Medicine, 2018, 50, 12-19.	2.2	30
45	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. PLoS ONE, 2018, 13, e0209343.	2.5	3
46	Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways. Frontiers in Immunology, 2018, 9, 809.	4.8	33
47	Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. Gastroenterology, 2018, 155, 311-315.e6.	1.3	73
48	DNA demethylation of inflammasome-associated genes is enhanced in patients with cryopyrin-associated periodic syndromes. Journal of Allergy and Clinical Immunology, 2017, 139, 202-211.e6.	2.9	57
49	Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. Autoimmunity Reviews, 2017, 16, 237-243.	5.8	25
50	Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Scientific Reports, 2017, 7, 43953.	3.3	52
51	Eosinophilic granulomatosis with polyangitis (Churg-Strauss) and severe pericardial effusion. Medicina ClÃ¡nica (English Edition), 2017, 148, e53.	0.2	0
52	Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. Annals of the Rheumatic Diseases, 2017, 76, 1624-1634.	0.9	67
53	Protocolo diagnÃ³stico de las vasculitis sistÃ©micas. Medicine, 2017, 12, 1739-1743.	0.0	0
54	Mujer de 75 aÃ±os con arteritis de cÃ©lulas gigantes y dolor torÃ¡cico. Medicine, 2017, 12, 1744.e1-1744.e4.	0.0	0

#	Article	IF	Citations
55	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
56	Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virusâ€"Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clinical Gastroenterology and Hepatology, 2017, 15, 575-583.e1.	4.4	99
57	Granulomatosis eosinofÃ¡lica con poliangitis (Churg-Strauss) y derrame pericÃ¡rdico grave. Medicina ClÃ¡nica, 2017, 148, e53.	0.6	0
58	Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. RMD Open, 2017, 3, e000570.	3.8	33
59	AB0575â€…Retrospective survey of concomitant autoimmune diseases and autoantibodies in a cohort of patients with anca-associated vasculitis (AAV). , 2017, , .		0
60	FRI0324â€…Small vessel vasculitis surrounding a preserved temporal artery: a diagnostic algorithm to assess clinical significance. , 2017, , .		0
61	Disease Phenotype and Outcome Depending on the Age at Disease Onset in Patients Carrying the R92Q Low-Penetrance Variant in TNFRSF1A Gene. Frontiers in Immunology, 2017, 8, 299.	4.8	41
62	An update on isolated retinal vasculitis. Minerva Oftalmologica, 2017, 59, .	0.1	0
63	Occlusive vasculopathy in human immunodeficiency virus (HIV)-associated vasculitis: unusual clinical and imaging course. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 185-188.	0.8	0
64	Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. Medicine (United States), 2016, 95, e2368.	1.0	55
65	The Expanding Role of Imaging in Systemic Vasculitis. Rheumatic Disease Clinics of North America, 2016, 42, 733-751.	1.9	30
66	Blocking interferon Î³ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. Annals of the Rheumatic Diseases, 2016, 75, 1177-1186.	0.9	89
67	Renal tubular acidosis type IV as a complication of lupus nephritis. Lupus, 2016, 25, 307-309.	1.6	8
68	Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. Autoimmunity Reviews, 2016, 15, 9-15.	5.8	62
69	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	6.2	144
70	Effect of Glucocorticoid Treatment on Computed Tomography Angiography Detected Large-Vessel Inflammation in Giant-Cell Arteritis. A Prospective, Longitudinal Study. Medicine (United States), 2015, 94, e486.	1.0	78
71	Evaluation of Aortic Inflammation Using Computed Tomographic Angiography: Vasculitis, Atherosclerosis, or Both. Journal of the American Geriatrics Society, 2015, 63, 415-416.	2.6	3
72	SomaticNLRP3mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. Annals of the Rheumatic Diseases, 2015, 74, 603-610.	0.9	104

#	Article	IF	Citations
73	Advances in the Diagnosis of Large Vessel Vasculitis. Rheumatic Disease Clinics of North America, 2015, 41, 125-140.	1.9	15
74	Epidemiological study of primary systemic vasculitides among adults in southern Spain and review of the main epidemiological studies. Clinical and Experimental Rheumatology, 2015, 33, S-11-8.	0.8	16
75	Small-vessel vasculitis with prominent IgG4 positive plasma cell infiltrates as potential part of the spectrum of IgG4-related disease: a case report. Clinical and Experimental Rheumatology, 2015, 33, S-138-41.	0.8	4
76	Influence of theIL17A locusin giant cell arteritis susceptibility. Annals of the Rheumatic Diseases, 2014, 73, 1742-1745.	0.9	36
77	Authorsâ€™ response to the eLetter by Moiseevet al. Annals of the Rheumatic Diseases, 2014, 73, e71-e71.	0.9	0
78	Single-Organ Gallbladder Vasculitis. Medicine (United States), 2014, 93, 405-413.	1.0	35
79	Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Annals of the Rheumatic Diseases, 2014, 73, 1826-1832.	0.9	103
80	Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis. Seminars in Arthritis and Rheumatism, 2014, 43, 772-777.	3.4	28
81	Diagnosis and classification of polyarteritis nodosa. Journal of Autoimmunity, 2014, 48-49, 84-89.	6.5	189
82	Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. Annals of the Rheumatic Diseases, 2014, 73, 616-623.	0.9	68
83	Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, caseâ€“control study. Annals of the Rheumatic Diseases, 2014, 73, 1388-1392.	0.9	148
84	Relapses in Patients With Giant Cell Arteritis. Medicine (United States), 2014, 93, 194-201.	1.0	158
85	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. PLoS ONE, 2014, 9, e113476.	2.5	17
86	Evidence of association of theNLRP1gene with giant cell arteritis. Annals of the Rheumatic Diseases, 2013, 72, 628-630.	0.9	23
87	Identification of thePTPN22functional variant R620W as susceptibility genetic factor for giant cell arteritis. Annals of the Rheumatic Diseases, 2013, 72, 1882-1886.	0.9	51
88	Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Annals of the Rheumatic Diseases, 2013, 72, 1481-1487.	0.9	96
89	OP0056â€…The PTPN22/CSK Signalling Pathway is Involved in Susceptibility to Develop Giant Cell Arteritis. Annals of the Rheumatic Diseases, 2013, 72, A68.3-A69.	0.9	0
90	FRI0232â€…Treatment with angiotensin II receptor-blockers is associated with lower relapse rate and reduced duration of treatment in patients with giant cell arteritis. Annals of the Rheumatic Diseases, 2013, 71, 392.3-393.	0.9	0

#	Article	IF	Citations
91	THU0222â€…Differences in clinical presentation and outcome in patients with early versus late onset giant-cell arteritis (GCA): Analysis of 94 patients. Annals of the Rheumatic Diseases, 2013, 71, 230.2-230.	0.9	1
92	THU0202â€…Prospective evaluation of aortic structural damage (aneurysm/dilatation) using a predefined screening protocol in biopsy-proven giant-cell arteritis patients during long-term follow-up. Annals of the Rheumatic Diseases, 2013, 71, 223.3-224.	0.9	2
93	Updating single-organ vasculitis. Current Opinion in Rheumatology, 2012, 24, 38-45.	4.3	69
94	B lymphocytes may play a significant role in large-vessel vasculitis. International Journal of Clinical Rheumatology, 2012, 7, 475-477.	0.3	2
95	Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. Rheumatology, 2012, 51, 841-851.	1.9	38
96	Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Annals of the Rheumatic Diseases, 2012, 71, 1170-1176.	0.9	300
97	Testicular Vasculitis. Medicine (United States), 2012, 91, 75-85.	1.0	42
98	Central Nervous System Vasculitis: Still More Questions than Answers. Current Neuropharmacology, 2011, 9, 437-448.	2.9	64
99	Treatment of Large Vessel Vasculitis. Current Immunology Reviews, 2011, 7, 435-442.	1.2	7
100	Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study. Rheumatology, 2011, 50, 2061-2070.	1.9	97
101	B-cell depletion therapy in patients with refractory Wegenerâ€™s granulomatosis with head and neck manifestations. International Journal of Clinical Rheumatology, 2010, 5, 29-32.	0.3	0
102	Surgical interventions and local therapy for Wegener's granulomatosis. Current Opinion in Rheumatology, 2010, 22, 29-36.	4.3	55
103	Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor Î± and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Research, 2010, 62, 835-841.	3.4	75
104	Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. Annals of the Rheumatic Diseases, 2010, 69, 434-442.	0.9	59
105	Treatment of Polymyalgia Rheumatica. Archives of Internal Medicine, 2009, 169, 1839.	3.8	104
106	Antineutrophil Cytoplasmic Antibody-Associated Vasculitides and Respiratory Disease. Chest, 2009, 136, 1101-1111.	0.8	92
107	Smallâ€vessel vasculitis surrounding an uninflamed temporal artery as a diagnostic criterion for polymyalgia rheumatica: Comment on the article by Chatelain et al. Arthritis and Rheumatism, 2009, 60, 2853-2854.	6.7	2
108	The spectrum of vascular involvement in giantâ€cell arteritis: clinical consequences of detrimental vascular remodelling at different sites. Apmis, 2009, 117, 10-20.	2.0	44

#	Article	IF	Citations
109	Gynecologic Vasculitis. Medicine (United States), 2009, 88, 169-181.	1.0	44
110	Limited Utility of Rapamycin in Severe, Refractory Wegenerâ€™s Granulomatosis. Journal of Rheumatology, 2009, 36, 116-119.	2.0	7
111	Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: A crossâ€sectional screening of fiftyâ€four prospectively followed patients. Arthritis and Rheumatism, 2008, 59, 422-430.	6.7	174
112	Arteriovenous malformation of the brain mimicking primary central nervous system vasculitis. Scandinavian Journal of Rheumatology, 2008, 37, 481-484.	1.1	1
113	Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Annals of the Rheumatic Diseases, 2008, 67, 1581-1588.	0.9	71
114	Vasculitis Involving the Breast. Medicine (United States), 2008, 87, 61-69.	1.0	35
115	Single-organ vasculitis. Current Opinion in Rheumatology, 2008, 20, 40-46.	4.3	52
116	Polyarteritis Nodosa. , 2008, , 87-92.		2
117	New therapeutic targets in giant-cell arteritis. Considerations based on the current pathogenic model and the availability of new therapeutic agents. Clinical and Experimental Rheumatology, 2008, 26, S141-50.	0.8	6
118	Gelatinase expression and proteolytic activity in giant-cell arteritis. Annals of the Rheumatic Diseases, 2007, 66, 1429-1435.	0.9	76
119	Development of Ischemic Complications in Patients With Giant Cell Arteritis Presenting With Apparently Isolated Polymyalgia Rheumatica. Medicine (United States), 2007, 86, 233-241.	1.0	38
120	Five Clinical Conundrums in the Management of Giant Cell Arteritis. Rheumatic Disease Clinics of North America, 2007, 33, 819-834.	1.9	26
121	Sustained spontaneous clinical remission in giant cell arteritis: Report of two cases with long-term followup. Arthritis and Rheumatism, 2006, 55, 160-162.	6.7	17
122	Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis*. Rheumatology, 2006, 45, 1356-1363.	1.9	64
123	Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis. Current Rheumatology Reports, 2004, 6, 184-194.	4.7	43
124	Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. Journal of Pathology, 2004, 204, 311-316.	4.5	88
125	Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis and Rheumatism, 2004, 51, 674-678.	6.7	48
126	Domains of health-related quality of life important to patients with giant cell arteritis. Arthritis and Rheumatism, 2003, 49, 819-825.	6.7	35

#	Article	IF	Citations
127	Tissue production of pro-inflammatory cytokines (IL-1Â, TNFÂ and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. British Journal of Rheumatology, 2003, 43, 294-301.	2.3	237
128	Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis. Circulation, 2003, 107, 2428-2434.	1.6	169
129	Tissue and Serum Angiogenic Activity Is Associated With Low Prevalence of Ischemic Complications in Patients With Giant-Cell Arteritis. Circulation, 2002, 106, 1664-1671.	1.6	99
130	A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis and Rheumatism, 2002, 46, 1309-1318.	6.7	480
131	A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis and Rheumatism, 2002, 47, 29-35.	6.7	127
132	Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathologic findings in a series of twenty-eight patients. Arthritis and Rheumatism, 2001, 44, 1387-1395.	6.7	105
133	Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: Inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis and Rheumatism, 2000, 43, 184-194.	6.7	128
134	Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Annals of the Rheumatic Diseases, 1999, 58, 189-192.	0.9	53
135	Interferon-? may exacerbate cryoglobulinemia-related ischemic manifestations: An adverse effect potentially related to its anti-angiogenic activity. Arthritis and Rheumatism, 1999, 42, 1051-1055.	6.7	68